


[Read ebook] Entry Inhibitors in HIV Therapy (Milestones in Drug Therapy)

## Entry Inhibitors in HIV Therapy (Milestones in Drug Therapy)

*From Brand: Birkhuser Basel*  
*audiobook | \*ebooks | Download PDF | ePub | DOC*



#9141127 in Books Birkhuser Basel 2007-08-17Original language:EnglishPDF # 1 9.25 x 6.25 x .75l, .0  
#File Name: 3764377828206 pages | File size: 66.Mb

**From Brand: Birkhuser Basel : Entry Inhibitors in HIV Therapy (Milestones in Drug Therapy)** before purchasing it in order to gage whether or not it would be worth my time, and all praised Entry Inhibitors in HIV Therapy (Milestones in Drug Therapy):

0 of 0 people found the following review helpful. Incredible IntensityBy R. DavisI get some of the greatest books at . This is no exception. I kid you not, this is one intense read. But, it should be. It's an intense subject. If you're looking for a quick and easy overview on the subject of Fusion Inhibitors, I wish you all the best in your search. If, on the other hand, you're looking to gain a real education on this subject, you have arrived.

Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors. A

unique overview of obstacles and accomplishments is presented. The impact of viral sequence diversity on this class of inhibitors is discussed, and a connection between basic research and clinical studies is shown. The book presents a unique collection of contributors from basic research, pharmaceutical research, and the clinic.

From the Back CoverEntry Inhibitors in HIV Therapy presents the current status of this relatively new and highly dynamic class of inhibitors and provides a unique overview of obstacles and considerations for HIV entry inhibition compared to other antiretroviral targets. The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss the challenge of genetic diversity in this region of the viral genome. Subsequent chapters feature current information on individual classes of entry inhibitors that target each step of the virus entry pathway, from attachment to membrane fusion. There is an emphasis on the complex determinants of entry inhibitor susceptibility, resistance mechanisms, the need for clinical phenotyping, and how these issues create new challenges for antiretroviral therapy. Encouraging pre-clinical studies of entry inhibitors as microbicides are also discussed. The final chapters highlight the current status of entry inhibitors in clinical studies, the major milestone achieved with FDA approval of enfuvirtide, and review drug development, past and present. In summary, this book presents a comprehensive and current overview of entry inhibitors from an expert panel of authors with diverse backgrounds and perspectives, incorporating many unrelenting successes against a backdrop of formidable challenges. It is of interest to basic science researchers as well as clinical physicians.